Skip to main content
Premium Trial:

Request an Annual Quote

Seeking 'Final Plan of Exit' for Array Business, Nanogen Starts Cutting Staff

NEW YORK (GenomeWeb News) - On the heels of Monday’s news that Nanogen is looking to sell, shut down, or find a partner for its microarray business, the company said today in a filing with the US Securities and Exchange Commission that it plans to trim its microarray workforce by 13 staffers, or around four percent.
Those staffers will be handed pink slips immediately, and Nanogen said more employee cuts may be on the way, depending on what the company decides will be its “final plan of exit,” the company said in the filing. 
This round of cuts will cost Nanogen around $335,000 in severance and related expenses.
Nanogen said Monday it wants to divest its microarray segment, which includes the NanoChip product line, in order to cut costs and focus on pursuing its clinical diagnostics strategy.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more